Former Zealand chief ready for phase III studies in new company
He managed Zealand Pharma until 2015 and now David Solomon has taken the reins in a US-based biotech company preparing for pivotal phase III studies of its key asset next year. When the drug enters the market it will compete with one of the world’s most expensive therapies.
BY MARTIN HAVTORN PETERSEN
From September 2008 to January 2015, David Solomon was CEO of Zealand Pharma where he was responsible for taking the company public in 2011 as the latest life science company to list on the Copenhagen Stock Exchange.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bionor Chairman: Solomon left of his own volition
For abonnenter
Solomon has Danish ambitions for Norwegian company
For abonnenter
Solomon lands new CEO position
For abonnenter
